World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
63247
World Ranking
5884
National Ranking
3153

Stevo Julius publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Stevo Julius sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 515 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Stevo Julius D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Stevo Julius sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Stevo Julius is affiliated with the University of Michigan-Ann Arbor in the United States. Their research predominantly falls within the field of Medicine, with a strong focus on Cardiology and Cardiovascular Medicine. Additional subfields in which they have published include Endocrinology, Diabetes and Metabolism, Surgery, Public Health, Environmental and Occupational Health, as well as Pulmonary and Respiratory Medicine.

The scientist has contributed extensively to topics related to blood pressure and hypertension, with notable emphasis on hormonal regulation and hypertension, heart rate variability and autonomic control, cardiovascular function and risk factors, atrial fibrillation management and outcomes, cardiovascular health and disease prevention, and diabetes treatment and management.

Recent papers authored or co-authored by Stevo Julius include:

  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure, 2021, The Lancet
  • Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death, 2021, The Lancet
  • Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis, 2021, The Lancet Oncology
  • Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes, 2022, The Lancet Diabetes & Endocrinology
  • Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg, 2023, Hypertension

Stevo Julius frequently collaborates with several researchers, most notably Sverre E. Kjeldsen, Kristian Wachtell, Giuseppe Mancia, Maria H. Mehlum, and Peter M. Okin.

The scientist's work is often published in journals such as Journal of Hypertension, Hypertension, Blood Pressure, Exploration of Medicine, and The Lancet. Their extensive output includes 8 publications in Journal of Hypertension, 4 in Hypertension, 4 in Blood Pressure, 4 in Exploration of Medicine, and 2 in The Lancet.

Stevo Julius has been recognized as a Member of the Association of American Physicians.

Best Publications

  • Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial

    Lennart Hansson;Alberto Zanchetti;S George Carruthers;Björn Dahlöf

  • Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

    Björn Dahlöf;Richard B Devereux;Sverre E Kjeldsen;Stevo Julius

  • Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

    Stevo Julius;Sverre E Kjeldsen;Michael Weber;Hans R Brunner

  • Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

    Lars H Lindholm;Hans Ibsen;Björn Dahlöf;Richard B Devereux

  • Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker

    Stevo Julius;Shawna D. Nesbitt;Brent M. Egan;Michael A. Weber

  • Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study

    Kristian Wachtell;Mika Lehto;Eva Gerdts;Michael H. Olsen

  • Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.

    Michael A Weber;Stevo Julius;Sverre E Kjeldsen;Hans R Brunner

  • Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.

    Peter M. Okin;Richard B. Devereux;Sverker Jern;Sverre E. Kjeldsen

  • Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study

    Kristian Wachtell;Hans Ibsen;Michael H. Olsen;Knut Borch-Johnsen

  • Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients. Losartan Intervention for Endpoint Reduction in Hypertension Study

    Hans Ibsen;Michael H. Olsen;Kristian Wachtell;Knut Borch-Johnsen

  • Mild high-renin essential hypertension. Neurogenic human hypertension?

    Murray Esler;Stevo Julius;Andrew Zweifler;Otelio Randall

  • The impact of serum uric acid on cardiovascular outcomes in the LIFE study

    Aud Høieggen;Michael H. Alderman;Sverre E. Kjeldsen;Stevo Julius

  • Heart rate and the cardiovascular risk

    Paolo Palatini;Stevo Julius

  • Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.

    Sverre E. Kjeldsen;Björn Dahlöf;Richard B. Devereux;Stevo Julius

  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

    Kazem Rahimi;Zeinab Bidel;Milad Nazarzadeh;Emma Copland

  • Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.

    Lars H. Lindholm;Hans Ibsen;Knut Borch-Johnsen;Michael Hecht Olsen

  • The sympathetic nervous system and the metabolic syndrome.

    Giuseppe Mancia;Pascal Bousquet;Jean Luc Elghozi;Murray Esler

  • The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.

    B Dahlöf;R Devereux;U de Faire;F Fyhrquist

  • Role of Parasympathetic Inhibition in the Hyperkinetic Type of Borderline Hypertension

    Stevo Julius;Arturo V. Pascual;Richard London

  • Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study

    Hans Ibsen;Kristian Wachtell;Michael H. Olsen;Knut Borch-JohnseN

Frequent Co-Authors

Sverre E. Kjeldsen
Sverre E. Kjeldsen University of Oslo
Richard B. Devereux
Richard B. Devereux Cornell University
Björn Dahlöf
Björn Dahlöf Sahlgrenska University Hospital
Markku S. Nieminen
Markku S. Nieminen University of Helsinki
Kristian Wachtell
Kristian Wachtell Cornell University
Peter M. Okin
Peter M. Okin Cornell University
Suzanne Oparil
Suzanne Oparil University of Alabama at Birmingham
Alberto Zanchetti
Alberto Zanchetti University of Milan
Paolo Palatini
Paolo Palatini University of Padua
Hans Wedel
Hans Wedel University of Gothenburg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Beyond traditional medical school, there are several online degree pathways that can open doors to rewarding careers in healthcare. Many students explore programs in nursing, medical billing, coding, or pursue advanced degrees to increase their job opportunities and earning potential.

For those interested in the administrative side of healthcare, learning about medical billing and coding certification cost can be an important step. These certifications are typically more affordable and require less time than a traditional degree.

Aspiring nurse practitioners and registered nurses can benefit from cheap np programs and by researching how much is online nursing school. There is growing demand for nurses and nurse practitioners, with flexible online options for completing both initial and advanced training.

For those looking to reach the highest level in nursing education, phd in nursing online programs offer opportunities to specialize in research, education, or leadership roles within the healthcare system. Online education makes these pathways more accessible and affordable than ever before.

Best Scientists Citing Stevo Julius

Trending Scientists

Recently Published Articles